Exploring 5-MeO-DALT. To explore a different substance…

Names:
5-MeO-DALT
5-Methoxy-DALT
N,N-Diallyl-5-methoxytryptamine
Tryptamine, N,N-diallyl-5-methoxy
Indole, 3-[2-(diallylamino)ethyl]-5-methoxy
3-[2-(Diallylamino)ethyl]-5-methoxyindole
IUPAC name:
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N-(prop-2-en-1-yl)prop-2-en-1-amine
5371 · C17H22N2O · 270.369
InChI=1S/C17H22N2O/c1-4-9-19(10-5-2)11-8-14-13-18-17-7-6-15(20-3)12-16(14)17/h4-7,12-13,18H,1-2,8-11H2,3H3
HGRHWEAUHXYNNP-UHFFFAOYSA-N This stereoisomer Any stereoisomer

Brandt, SD; Tirunarayanapuram, SS; Freeman, S; Dempster, N; Barker, SA; Daley, PF; Cozzi, NV; Martins, CPB. Microwave-accelerated synthesis of psychoactive deuterated N,N-dialkylated-[α,α,β,β-d4]-tryptamines. J. Labelled Compd. Radiopharm., 1 Nov 2008, 51 (14), 423–429. 169 kB. https://doi.org/10.1002/jlcr.1557

Corkery, JM; Durkin, E; Elliott, S; Scchifano, F; Ghodse, AH. The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review. Prog. Neuro-Psychopharmacol. Biol. Psych., 1 Dec 2012, 39 (1), 259—262. 307 kB. https://doi.org/10.1016/j.pnpbp.2012.05.022

Jovel, A; Felthous, A; Bhattacharyya, A. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J. Forensic Sci., 1 May 2014, 59 (3), 844–846. 91 kB. https://doi.org/10.1111/1556-4029.12367

Brandt, SD; Kavanagh, PV; Dowling, G; Talbot, B; Westphal, F; Meyer, MR; Maurer, HH; Halberstadt, AL. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives. Drug Test. Analysis, 1 Jan 2017, 9 (1), 115-126. 1.3 MB. https://doi.org/10.1002/dta.1974 Open access DOI

Arunotayanun, W; Dalley, JW; Huang, X; Setola, V; Treble, R; Iversen, L; Roth, BL; Gibbons, S. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: Emerging ‘novel psychoactive drugs’. Bioorg. Med. Chem. Lett., 1 Jun 2013, 23 (11), 3411-3415. 1.1 MB. https://doi.org/10.1016/j.bmcl.2013.03.066 #18

Dinger, J; Woods, C; Brandt, SD; Meyer, MR; Maurer, HH. Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol. Lett., 2016, 241, 82-94. 2.6 MB. https://doi.org/10.1016/j.toxlet.2015.11.013

Cozzi, NV; Daley, PF. Receptor binding profiles and quantitative structure–affinity relationships of some 5-substituted-N,N-diallyltryptamines. Bioorg. Med. Chem. Lett., 2016, 26 (3), 959-964. 513 kB. https://doi.org/10.1016/j.bmcl.2015.12.053

Meyer, MR; Caspar, A; Brandt, SD; Maurer, HH. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Anal. Bioanal. Chem., 1 Jan 2014, 406 (1), 225–237. 457 kB. https://doi.org/10.1007/s00216-013-7425-9

Brandt, SD; Martins, CP. Analytical methods for psychoactive N,N-dialkylated tryptamines. Trends Anal. Chem., 1 Sep 2010, 29 (8), 858–869. 446 kB. https://doi.org/10.1016/j.trac.2010.04.008 #40

Klein, LM; Cozzi, NV; Daley, PF; Brandt, SD; Halberstadt, AL. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs. Neuropharmacology, 1 Feb 2018, n/a. 882 kB. https://doi.org/10.1016/j.neuropharm.2018.02.028

Caspar, AT; Gaab, JB; Michely, JA; Brandt, SD; Meyer, MR; Maurer, HH. Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC–MS, LC–MSn, and LC-HR-MSMS. Drug Test. Analysis, 1 Jan 2018, 10 (1), 184–195. 546 kB. https://doi.org/10.1002/dta.2197

Jones, LE; Stewart, A; Peters, KL; McNaul, M; Speers, SJ; Fletcher, NC; Bell, SEJ. Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples. Analyst, 25 Jan 2016, 141 (3), 902–909. 8.6 MB. https://doi.org/10.1039/c5an02326b

Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products. Drug Test. Analysis, 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315

Nichols, DE. Chemistry and structure–activity relationships of psychedelics. In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 1-43. 2.6 MB. https://doi.org/10.1007/7854_2017_475 #18

Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. Supplementary Data. BLOTTER, 1 Mar 2018, 3 (1). 5.7 MB. https://doi.org/10.16889/isomerdesign-5-supp Open access DOI

Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. BLOTTER, 1 Mar 2018, 3 (1). 1.2 MB. https://doi.org/10.16889/isomerdesign-5 Open access DOI

4-MeO-DALT
9366
19 June 2018 · Creative Commons BY-NC-SA ·